GER
MCID: GST092
MIFTS: 60

Gastroesophageal Reflux (GER)

Categories: Cancer diseases, Gastrointestinal diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Gastroesophageal Reflux

MalaCards integrated aliases for Gastroesophageal Reflux:

Name: Gastroesophageal Reflux 57 11 75 28 12 5 43 14
Gastroesophageal Reflux Disease 57 11 53 14 16 71 75
Gerd 57 11 41
Gerd - Gastro-Esophageal Reflux Disease 11
Gastroesophageal Reflux, Pediatric 57
Gastro-Esophageal Reflux 11
Gastresophageal Reflux 11
Acid Reflux 11
Ger 57

Characteristics:


Inheritance:

Autosomal dominant 57

Classifications:



External Ids:

Disease Ontology 11 DOID:8534
OMIM® 57 109350
ICD9CM 34 530.81
MeSH 43 D005764
NCIt 49 C26781
SNOMED-CT 68 235595009
ICD10 31 K21.9
MedGen 40 C0017168
UMLS 71 C0017168

Summaries for Gastroesophageal Reflux

MedlinePlus: 41 Your esophagus is the tube that carries food from your mouth to your stomach. Gastroesophageal reflux disease (GERD) happens when a muscle at the end of your esophagus does not close properly. This allows stomach contents to leak back, or reflux, into the esophagus and irritate it. You may feel a burning in the chest or throat called heartburn. Sometimes, you can taste stomach fluid in the back of the mouth. If you have these symptoms more than twice a week, you may have GERD. You can also have GERD without having heartburn. Your symptoms could include a dry cough, asthma symptoms, or trouble swallowing. Anyone, including infants and children, can have GERD. If not treated, it can lead to more serious health problems. In some cases, you might need medicines or surgery. However, many people can improve their symptoms by: Avoiding alcohol and spicy, fatty or acidic foods that trigger heartburn Eating smaller meals Not eating close to bedtime Losing weight if needed Wearing loose-fitting clothes NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary: Gastroesophageal Reflux, also known as gastroesophageal reflux disease, is related to hernia, hiatus and esophagitis, and has symptoms including nausea and vomiting, constipation and abdominal pain. An important gene associated with Gastroesophageal Reflux is CHAT (Choline O-Acetyltransferase), and among its related pathways/superpathways are Signal Transduction and Thermogenesis. The drugs Dopamine and Domperidone have been mentioned in the context of this disorder. Affiliated tissues include kidney, lung and tongue, and related phenotypes are gastroesophageal reflux and esophagitis

OMIM®: 57 Gastroesophageal reflux (GER) is characterized by the retrograde movement of stomach contents into the esophagus. In its most severe form, GER results in extensive tissue damage caused by acid reflux. In adolescents and adults, and even infrequently in children, chronic GER is associated with the risk of developing Barrett metaplasia (614266), a premalignant lesion of the esophageal mucosa (Hu et al., 2000). In turn, Barrett metaplasia is correlated with the development of adenocarcinoma of the esophagus (see 614266), estimated as the fifth most prevalent neoplasia in the Western world (Lagergren et al., 1999). (109350) (Updated 08-Dec-2022)

Wikipedia: 75 Gastroesophageal reflux disease (GERD) or gastro-oesophageal reflux disease (GORD) is one of the upper... more...

Related Diseases for Gastroesophageal Reflux

Diseases related to Gastroesophageal Reflux via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 775)
# Related Disease Score Top Affiliating Genes
1 hernia, hiatus 33.2 MLN HRH2 GAST CYP2C19
2 esophagitis 33.0 TP53 MLN HRH2 GAST CYP2C19 CCL26
3 peptic esophagitis 33.0 MLN HRH2 GAST CYP2C19 CCL26
4 dyskinesia of esophagus 32.2 MLN HRH2 CCL26
5 gastroparesis 32.1 MLN HRH2 GAST CCK
6 gastritis 32.1 TP53 HRH2 GAST CYP2C19
7 gastrointestinal system disease 32.1 MLN GCG GAST CCK
8 peptic ulcer disease 32.0 HRH2 GAST CYP2C19 CCK
9 irritable bowel syndrome 31.9 PYY MLN GCG CCK
10 duodenal ulcer 31.8 MLN HRH2 GAST CYP2C19 CCK
11 achalasia 31.8 TP53 GMPPA GAST CHAT
12 duodenogastric reflux 31.6 PYY MLN GAST CCK
13 bile reflux 31.5 GAST CCK
14 gastric ulcer 31.5 HRH2 GAST CYP2C19
15 dumping syndrome 31.5 PYY MLN GCG GAST CCK
16 nutritional deficiency disease 31.4 PYY GAST CCK
17 volvulus of midgut 31.3 PYY MLN GCG CCK
18 body mass index quantitative trait locus 11 31.2 TP53 PYY MLN GCG CCK ABCC8
19 celiac disease 1 31.2 PYY GCG GAST CCK
20 diarrhea 31.2 PYY MLN HRH2 GAST CCK
21 duodenitis 31.2 GAST CCK
22 diabetes mellitus 31.1 TP53 PYY MLN GCG GAST CYP2C19
23 autonomic neuropathy 31.1 MLN GCG GAST CCK
24 gastroduodenitis 31.1 GAST CCL26
25 zollinger-ellison syndrome 31.1 MLN HRH2 GAST
26 active peptic ulcer disease 31.0 HRH2 CYP2C19
27 bowel dysfunction 30.8 PYY MLN GCG CCK
28 gastroenteritis 30.8 PYY MLN HRH2
29 anorexia nervosa 30.7 PYY GCG CCK
30 postcholecystectomy syndrome 30.6 MLN GAST CCK
31 gallbladder disease 30.6 TP53 PYY MLN CCK
32 short bowel syndrome 30.6 PYY GCG GAST CCK
33 hyperglycemia 30.5 PYY GCG CCK ABCC8
34 esophageal candidiasis 30.5 CYP2C19 CCL26
35 hypertrophic pyloric stenosis 30.5 MLN GAST
36 glossitis 30.3 GCG GAST
37 neuropathy, hereditary sensory and autonomic, type i, with cough and gastroesophageal reflux 11.8
38 spastic paraplegia 9a, autosomal dominant 11.7
39 barrett esophagus 11.6
40 intellectual developmental disorder, autosomal dominant 47 11.5
41 dihydropyrimidinase deficiency 11.3
42 microcephaly, growth restriction, and increased sister chromatid exchange 2 11.3
43 down syndrome 11.3
44 neuropathy, hereditary sensory and autonomic, type iii 11.3
45 cardiospondylocarpofacial syndrome 11.2
46 intellectual developmental disorder, x-linked 98 11.2
47 kilquist syndrome 11.2
48 multiple congenital anomalies-hypotonia-seizures syndrome 11.2
49 spastic paraplegia 9 11.2
50 gas bloat syndrome 11.2

Comorbidity relations with Gastroesophageal Reflux via Phenotypic Disease Network (PDN): (show all 12)


Acute Cystitis Anxiety
Bronchitis Deficiency Anemia
Dyskinesia of Esophagus Esophagitis
Heart Disease Hypertension, Essential
Hypothyroidism Intermediate Coronary Syndrome
Osteoporosis Peptic Esophagitis

Graphical network of the top 20 diseases related to Gastroesophageal Reflux:



Diseases related to Gastroesophageal Reflux

Symptoms & Phenotypes for Gastroesophageal Reflux

Human phenotypes related to Gastroesophageal Reflux:

30
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 gastroesophageal reflux 30 HP:0002020
2 esophagitis 30 HP:0100633
3 barrett esophagus 30 HP:0100580

Symptoms via clinical synopsis from OMIM®:

57 (Updated 08-Dec-2022)
G I:
gastroesophageal reflux
chronic ulcerating esophagitis

Lab:
columnar epithelium-lined distal esophagus

Oncology:
adenocarcinoma of the esophagus risk about 10%

Clinical features from OMIM®:

109350 (Updated 08-Dec-2022)

UMLS symptoms related to Gastroesophageal Reflux:


nausea and vomiting; constipation; abdominal pain; diarrhea; dyspepsia; icterus; heartburn; gastrointestinal gas

Drugs & Therapeutics for Gastroesophageal Reflux

Drugs for Gastroesophageal Reflux (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 223)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4 62-31-7, 51-61-6 681
2
Domperidone Approved, Investigational, Vet_approved Phase 4 57808-66-9 3151
3
Zinc cation Approved, Experimental, Investigational Phase 4 7440-66-6, 23713-49-7 32051
4
Mometasone furoate Approved, Investigational, Vet_approved Phase 4 83919-23-7 4240 441336
5
Trimebutine Approved Phase 4 39133-31-8 5573
6
Rabeprazole Approved, Investigational Phase 4 117976-89-3, 117976-90-6 5029
7
Calcium polycarbophil Approved Phase 4 126040-58-2
8
Magnesium hydroxide Approved, Investigational Phase 4 1309-42-8
9
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
10
Tannic acid Approved Phase 4 1401-55-4 16129878 16129778
11
Metoclopramide Approved, Investigational Phase 4 364-62-5 4168
12
Nortriptyline Approved Phase 4 72-69-5 4543
13
Rebamipide Approved, Investigational Phase 4 90098-04-7 5042
14
Citalopram Approved Phase 4 59729-32-7, 59729-33-8 2771
15
Dimercaprol Approved Phase 4 59-52-9 3080
16
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
17
Clarithromycin Approved Phase 4 81103-11-9 84029
18
Dronabinol Approved, Illicit Phase 4 1972-08-3 16078
19
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
20
Prucalopride Approved Phase 4 179474-81-8 3052762
21
Cisapride Approved, Investigational, Withdrawn Phase 4 81098-60-4 6917698 2769
22
Indobufen Investigational Phase 4 63610-08-2 107641
23
Maleic acid Experimental, Investigational Phase 4 110-16-7, 110-17-8 444266 444972
24
Carnosine Experimental, Investigational Phase 4 305-84-0, 107667-60-7 439224
25
Mosapride Investigational Phase 4 112885-41-3 119584
26
Dexetimide Withdrawn Phase 4 21888-98-2 30843
27 Antirheumatic Agents Phase 4
28 Fibrinolytic Agents Phase 4
29 Antipyretics Phase 4
30 Cyclooxygenase Inhibitors Phase 4
31 Dopamine Antagonists Phase 4
32 Dopamine Agents Phase 4
33 Antiemetics Phase 4
34 Cytochrome P-450 CYP3A Inhibitors Phase 4
35 Parasympatholytics Phase 4
36 Analgesics Phase 4
37 Analgesics, Non-Narcotic Phase 4
38 Calcium, Dietary Phase 4
39 Hormones Phase 4
40 Hormone Antagonists Phase 4
41 Psyllium Phase 4
42 Aluminum hydroxide, magnesium hydroxide, simethicone drug combination Phase 4
43
TEMPO Phase 4
44 Acidophilus Phase 4
45 Adrenergic Agents Phase 4
46 Antidepressive Agents, Tricyclic Phase 4
47 Antidepressive Agents Phase 4
48 Serotonin Uptake Inhibitors Phase 4
49 Hallucinogens Phase 4
50 Anti-Anxiety Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 975)
# Name Status NCT ID Phase Drugs
1 Effect of Indobufen Versus Aspirin on Gastric Acid Secretion and Gastroesophageal Reflux in Patients With Coronary Heart Disease and Gastroesophageal Reflux Disease Undergoing Dual Antiplatelet Therapy: a Prospective, Randomized, Double-blind, Double-dummy, Positive Drug Parallel Control Clinical Trials Unknown status NCT04129008 Phase 4 Indobufen and aspirin mimetic;Aspirin and indobufen mimetic
2 The Relationship Between Gastroesophageal Reflux and Pediatric Rhinitis: Significance of Pale/Blue Colored Turbinate. A Randomized Controlled Trial Unknown status NCT02278081 Phase 4 lansoprazole;placebo
3 Research of Efficient Use of Omeprazole in Combination With Domperidone in Gastroesophageal Reflux Disease of Mild to Moderate Severity Unknown status NCT02140073 Phase 4 omeprazole+domperidone SR;omeprazole
4 A Randomized, Double-Blind, Placebo-Controlled Study of Gastroesophageal Reflux Disease Therapy ( Lansoprazole; Solutab) in the Management of Childhood Asthma Unknown status NCT00237068 Phase 4 Lansoprazole; Solutab
5 Effectiveness of Vonoprazan vs Omeprazole as Empiric Therapy for Gastroesophageal Reflux Disease (GERD) Patients Without Alarm Features in a Primary Care Setting: A Pragmatic, Randomized, Single Blind Study Unknown status NCT04028466 Phase 4 Vonoprazan;Omeprazole
6 Effect of Magnesium Alginate on Gastroesophageal Reflux in Infants. Unknown status NCT02806453 Phase 4
7 Randomized, Double Blind, Placebo Control Trial to Evaluate the Efficacy of Wu-Chu-Yu Tang on Gastroesophageal Reflux Disease (GERD) Unknown status NCT01822106 Phase 4
8 Effectiveness of Lactobacillus GG in the Prevention of Gastrointestinal and Respiratory Tract Infections in Children With Gastroesophageal Reflux Disease Treated With Proton Pump Inhibitors: Randomized Double - Blind Placebo, Controlled Trial. Unknown status NCT01782118 Phase 4
9 Efficacy of Zinc L-carnosine (Hepilor®) in Maintaining Remission of Gastroesophageal Reflux Disease: a Randomised, Double-blind, Placebo-controlled Study Unknown status NCT03467438 Phase 4 Zinc-l-carnosine
10 Effective Mechanisms of Wu-Chu-Yu Tang on Gastroesophageal Disorder Unknown status NCT04118647 Phase 4 Wu-Chu-Yu tang
11 Clinical Trial: Esomeprazole Plus Alginate vs. Esomeprazole Alone for Treatment of Nighttime Reflux Symptom and GERD-related Sleep Disturbances in Patients With Erosive GERD Unknown status NCT02277886 Phase 4 sodium alginate;esomeprazole
12 Comparing Dexlansoprazole With Double-dose Lansoprazole to Achieve Sustained Symptomatic Response in Overweight and Obesity Patients With Reflux Esophagitis in Los Angeles Grades A & B Unknown status NCT02759393 Phase 4 Dexlansoprazole;Lansoprazole
13 Symptom Assessment for Patients With Gastro-esophageal Reflux Disease Receiving Helicobacter Pylori Eradication Unknown status NCT02934152 Phase 4 H pylori eradication
14 The Clinical Efficacy and Safety of Trimebutine Maleate Combined With Rabeprazole in Patients With Grade A or B Reflux Esophagitis Whose Symptoms Refractory to Rabeprazole Unknown status NCT02986685 Phase 4 Trimebutine Maleate;rabeprazole
15 A Placebo-controlled Trial With Prucalopride for the Treatment of Typical Reflux Symptoms in Patients With Gastro-esophageal Reflux Disease With Incomplete Proton Pump Inhibitor Response Unknown status NCT03676374 Phase 4 Prucalopride;Placebo Oral Tablet
16 A Randomized, Double-blind, Placebo-controlled Study of Dexlansoprazole to Treat Laryngopharyngeal Reflux and Lingual Tonsil Hypertrophy Unknown status NCT01328652 Phase 4 dexlansoprazole
17 Cardiac Safety Evaluation of Lansoprazole/Domperidone 30/30 mg Sustained Release Capsule Formulation Unknown status NCT03355170 Phase 4 Lansoprazole
18 A Placebo-controlled Trial With Citalopram for the Treatment of Typical Reflux Symptoms in Patients With Reflux Hypersensitivity or Functional Heartburn With Incomplete Proton Pump Inhibitor Response Unknown status NCT03499171 Phase 4 Citalopram 20mg;Placebo Oral Tablet
19 Effects of Esomeprazole on Gastric Emptying of Alcoholic Beverages, Blood Alcohol Concentrations, Gastroesophageal Reflux and Release of Some Gastrointestinal Hormones in Healthy Volunteers Completed NCT00472550 Phase 4 esomeprazole 20 mg
20 Evaluation of Smectite Effect As A Food Thickener On Gastroesophageal Reflux Disease In Neonates Using Combined Esophageal Multichannel Intraluminal Impedance Completed NCT04788485 Phase 4 Diosmectite
21 An Open Label, Multicentre Study of Nexium (Esomeprazole) 40 mg Once Daily in Subjects With Symptoms of Gastroesophageal Reflux Disease (GORD) After Treatment With a Full Dose of Proton Pump Inhibitor (PPI) Completed NCT00734097 Phase 4 Esomeprazole 40 mg
22 An Open, Randomized, Two-way Crossover Study Comparing the Effect of 40mg Esomeprazole Administered Orally and Intravenously as a 15 Minute Infusion on Basal and Pentagastrin-Stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Disease (GERD). Completed NCT00635414 Phase 4 Esomeprazole
23 Phase IV Non Comparative Study of the Impact of Dietary Fiber Deficiency Correction Using Mucofalk® on Clinical Features and Motor Function of the Esophagus in Patients With Non-erosive Gastroesophageal Reflux Disease Completed NCT01882088 Phase 4 Mucofalk
24 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Efficacy Study Comparing 4 Weeks of Treatment With Esomeprazole 20 mg qd to Placebo qd in Patients With Heartburn and Sleep Disturbances Associated With Gastroesophageal Reflux Disease (GERD) Completed NCT00660660 Phase 4 Esomeprazole;Placebo
25 Role of Mosapride in Patients With Gastroesophageal Reflux Disease Completed NCT00729339 Phase 4 mosapride for the first month and placebo for the 2nd month;placebo for the first and mosapride for the second month
26 A Study to Assess the Effectiveness of Esomeprazole 40 mg Once Daily in Subjects With Continuing Gastroesophageal Reflux Disease (GORD) Symptoms Following Treatment Wit a Previous Full Dose Proton Pump Inhibitor (PPI) Completed NCT00384592 Phase 4 Esomeprazole
27 A Phase III, Multicentre, Randomized, Double-blind Parallel-group Study to Evaluate the Safety and Clinical Outcome of Once Daily Esomeprazole for the Treatment of Gastroesophageal Reflux Disease (GERD) in Pediatric Patients 1 to 11 Years of Age, Inclusive. Completed NCT00228527 Phase 4 Esomeprazole (Nexium)
28 The Influence of CYP2C19 Genetic Polymorphism and Dosage of Rabeprazole on the Accuracy of Proton-Pump Inhibitor Testing in Chinese Patients With Gastroesophageal Reflux Disease Completed NCT00354757 Phase 4 rabeprazole
29 The Impact of Gastroesophageal Reflux Disease in Sleep Disorders: A Pilot Investigation of Rabeprazole, 20 mg Twice Daily for the Relief of GERD-Related Insomnia. Completed NCT00287391 Phase 4 Rabeprazole
30 A Randomised, Open, Phase IV, Parallel Group Multicentre Study to Evaluate a Change of Management in Gastroesophageal Reflux Disease (GERD) Patients by Treatment With Esomeprazole 40 mg or Any Other Proton Pump Inhibitor (PPI), After Initial Treatment Failure, in Ordinary Clinical Practice During 4 Weeks. Completed NCT00272701 Phase 4 Esomeprazole;Other PPI marketed in Sweden
31 Determination of the Minimal Clinically Important Difference (MCID) of the Patient Orientated Self Assessment Scale ReQuest TradeMark in Patients Suffering From Endoscopically Confirmed Gastroesophageal Reflux Disease (GERD), Grade A-D According to Los Angeles Classification Treated With Pantoprazole 40 mg o.d. or Placebo o.d. Over One Week. Completed NCT00246909 Phase 4 Pantoprazole
32 An Open-Label Study of Once-Daily Oral Administration of Esomeprazole 40 mg in Patients With Symptoms of Gastroesophageal Reflux Disease (GERD) to Investigate the Relationship Between the Presence of Erosive Esophagitis (EE) at Baseline and Heartburn Resolution After 4 Weeks of Treatment Completed NCT00242736 Phase 4 Esomeprazole
33 An Open, Randomised Two Way Crossover Study Comparing the Effects of 40mg of Esomeprazole Adminstered Orally and Intravenously as a 3 Minute Injection on Basal and Pentrigastrin-stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Disease (GERD) Completed NCT00625495 Phase 4 Esomeprazole
34 A Pilot Study Comparing Clinical Efficacy of One-Week Dual Delayed-Release Dexlansoprazole 60 mg and Esomeprazole 40 mg for Gastroesophageal Reflux Disease Grade A and B Completed NCT03128736 Phase 4 Esomeprazole group;Dexlansoprazole group
35 The Role of Anti-Reflux Surgery for Gastroesophageal Reflux Disease in Premature Infants With Bronchopulmonary Dysplasia (BPD). Completed NCT00926276 Phase 4
36 A Phase 4, Open-Label Study in Patients From Asia With Gastroesophageal Reflux Disease Treated With Dexlansoprazole Completed NCT02351960 Phase 4 Dexlansoprazole
37 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Efficacy Study Comparing 4 Weeks of Treatment With Esomeprazole 20 mg qd and 40 mg qd to Placebo qd in Patients With Heartburn and Sleep Disturbances Associated With Gastroesophageal Reflux Disease (GERD) Completed NCT00628342 Phase 4 Esomeprazole;Placebo
38 An Open, Randomized, Two Way Crossover Study Comparing the Effect of 20mg Esomeprazole Administered Orally and Intravenously as a 15 Minute Infusion on Basal and Pentagastrin-Stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Disease (GERD) Completed NCT00629564 Phase 4 Esomeprazole
39 Laparoscopic Nissen Fundoplication Combined With Posterior Gastropexy in Surgical Treatment of Gastroesophageal Reflux Disease Completed NCT00872755 Phase 4
40 An Open, Randomised Two Way Crossover Study Comparing the Effects of 20mg of Esomeprazole Administered Orally and Intravenously as a 3 Minute Injection on Basal and Pentagastrin-stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Disease (GERD) Completed NCT00626262 Phase 4 Esomeprazole
41 Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Assess Management Strategies for the Use of Esomeprazole (Nexium) in Helicobacter Pylori Infected Patients With Gastroesophageal Reflux Disease (GERD) Completed NCT00574925 Phase 4 Esomeprazole
42 Use of Metoclopramide for the Prevention of Gastroesophageal Reflux in Premature Infants Followed in an Outpatient Kangaroo Mother Care Clinic Before 40 Weeks of Gestational Age: A Randomized Controlled Trial Completed NCT02907632 Phase 4 Metoclopramide;Placebo
43 Implementation of Pharmacogenomic Testing in Nemours Children's Health System Completed NCT02794844 Phase 4 Genotype Guided PPI Dosing
44 Phase 4 Study, Assessing the Efficacy of Lansoprazole and Domperidone Combination on Intragastric and Intraesophageal Acidity Completed NCT02958046 Phase 4 Lansoprazole/Domperidone
45 Evaluation of Patients With Non-cardiac Chest Pain Using PillCam Eso - a Wireless Imaging Capsule of the Esophagus. Completed NCT00476398 Phase 4
46 A Multi-centred, Phase IV, Post-Marketing, Prospective, Randomized, Double-Blind Study Comparing Esomeprazole Magnesium 40mg Once Daily Versus Lansoprazole 30 mg Twice Daily in Symptom Control of Subjects With Persistent Gastrooesophageal Reflux Disease While on 30mg Once Daily Lansoprazole Therapy Completed NCT00637845 Phase 4 Esomeprazole Magnesium;Lansoprazole
47 Comparison of the Effect of Rabeprazole 50 mg DDR Capsules and 20 mg Enteric-coated Tablets on Intragastric and Intraesophageal Acidity Completed NCT03037606 Phase 4 Rabelis DDR 50 mg Capsules;Pariet 20 mg Enteric Coated Tablets
48 A Cluster-Randomized Study to Examine National Characteristics and Outcome Measures of GERD Patients Utilizing the PPI Acid Suppression Symptom (PASS) Test for Response [EncomPASS]. Completed NCT00392002 Phase 4 Esomeprazole
49 Role of Esophageal and Laryngeal Biopsies in Suspected Laryngopharyngeal Reflux Completed NCT00373997 Phase 4
50 A Multicenter, Randomized, Double-blinded, Placebo-controlled Pilot Study to Evaluate the Efficacy and Safety of Rebamipide as an Adjuvant Regimen to Heal erosIve Reflux Esophagitis (REPAIR) Completed NCT02755753 Phase 4 Lansoprazole;Rebamipide;Rebamipide-placebo

Search NIH Clinical Center for Gastroesophageal Reflux

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Aluminum carbonate
Aluminum Hydroxide
Aluminum Hydroxide / Magnesium Hydroxide
Aluminum Hydroxide Gel
aluminum hydroxide, dried (USP)
basic aluminum carbonate gel
Bethanechol
Bethanechol Chloride
Calcium Carbonate
CALCIUM CARBONATE 1 g in 1 g ORAL POWDER
Calcium gluceptate
Cimetidine
Cimetidine Hydrochloride
Cisapride
dihydroxyaluminum sodium carbonate
Esomeprazole
Esomeprazole magnesium
esomeprazole sodium
Esomeprazole Strontium
Famotidine
Isosorbide
Isosorbide Dinitrate
Isosorbide Mononitrate
lansoprazole
magaldrate
magnesium carbonate
MAGNESIUM CARBONATE BLOCKS
Magnesium Hydroxide
magnesium trisilicate
Metoclopramide
Metoclopramide Hydrochloride
MILK OF MAGNESIA
Nizatidine
Omeprazole
Omeprazole 2 MG/ML Oral Suspension
Omeprazole magnesium
pantoprazole
Pantoprazole sodium
rabeprazole
Sodium Bicarbonate
SODIUM BICARBONATE PWDR

Cochrane evidence based reviews: gastroesophageal reflux

Genetic Tests for Gastroesophageal Reflux

Genetic tests related to Gastroesophageal Reflux:

# Genetic test Affiliating Genes
1 Gastroesophageal Reflux 28

Anatomical Context for Gastroesophageal Reflux

Organs/tissues related to Gastroesophageal Reflux:

MalaCards : Kidney, Lung, Tongue, Spinal Cord, Heart, Tonsil, Bone

Publications for Gastroesophageal Reflux

Articles related to Gastroesophageal Reflux:

(show top 50) (show all 25280)
# Title Authors PMID Year
1
Fine mapping a gene for pediatric gastroesophageal reflux on human chromosome 13q14. 62 57
15014979 2004
2
Refined localization of a gene for pediatric gastroesophageal reflux makes HTR2A an unlikely candidate gene. 62 57
11140952 2000
3
Mapping of a gene for severe pediatric gastroesophageal reflux to chromosome 13q14. 62 57
10891964 2000
4
Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. 62 57
10080844 1999
5
Evaluation and management of gastroesophageal reflux disease: A brief look at the updated guidelines. 62 41
36455971 2022
6
Triglyceride-glucose index is associated with gastroesophageal reflux disease and erosive reflux disease: a health checkup cohort study. 62 41
36470993 2022
7
Gastroesophageal reflux related changes after sleeve gastrectomy and sleeve gastrectomy with fundoplication: A retrospective single center study. 62 41
36465617 2022
8
Mutations in GMPPA cause a glycosylation disorder characterized by intellectual disability and autonomic dysfunction. 5
24035193 2013
9
Esomeprazole reduces gastroesophageal reflux after beer consumption in healthy volunteers. 53 62
18924018 2008
10
Influence of cytochrome P450 2C19 genetic polymorphism and dosage of rabeprazole on accuracy of proton-pump inhibitor testing in Chinese patients with gastroesophageal reflux disease. 53 62
17559380 2007
11
Gastric emptying of glucose solution and associated plasma concentrations of GLP-1, GIP, and PYY before and after fundoplication. 53 62
17200910 2007
12
Helicobacter pylori infection is the major risk factor for gastric inflammation in the cardia. 53 62
16602036 2006
13
Sporadic versus hereditary gastrinomas of the duodenum and pancreas: distinct clinico-pathological and epidemiological features. 53 62
17006979 2006
14
[Roles of bile and gastrin in the pathogenesis of childhood gastroesophageal reflux disease]. 53 62
16923358 2006
15
The transient receptor potential vanilloid 1: role in airway inflammation and disease. 53 62
16464449 2006
16
Short report: Autistic gastrointestinal and eating symptoms treated with secretin: a subtype of autism. 53 62
16287506 2005
17
Comparative study of nizatidine and famotidine for maintenance therapy of erosive esophagitis. 53 62
15683433 2005
18
Edkins and a century of acid suppression. 53 62
16172550 2005
19
Quantitative, tissue-specific analysis of cyclooxygenase gene expression in the pathogenesis of Barrett's adenocarcinoma. 53 62
15585388 2004
20
The relationship between the esophageal tissue content of neurotensin and the presence or absence of esophageal inflammation. 53 62
14992433 2004
21
Colonization with cagA-positive Helicobacter pylori strains in intestinal metaplasia of the esophagus and the esophagogastric junction. 53 62
12907324 2003
22
[Modern aspects of treating gastroesophageal reflux disease]. 53 62
12664775 2003
23
[A study on the relationship of Helicobacter pylori, gastrin and gastroesophageal reflux disease]. 53 62
12812673 2003
24
Role of CCK(A) receptors in postprandial lower esophageal sphincter function in morbidly obese subjects. 53 62
12452391 2002
25
The effect of cholecystectomy on plasma cholecystokinin. 53 62
12358231 2002
26
Effects of ABT-229, a motilin agonist, on acid reflux, oesophageal motility and gastric emptying in patients with gastro-oesophageal reflux disease. 53 62
12182748 2002
27
Effects of adjustable gastric banding on altered gut neuropeptide levels in morbidly obese patients. 53 62
11775572 2001
28
The importance of vacA, cagA, and iceA genotypes of Helicobacter pylori infection in peptic ulcer disease and gastroesophageal reflux disease. 53 62
11569682 2001
29
Restoration of enamel and dentin erosion due to gastroesophageal reflux disease: a case report. 53 62
11402771 2001
30
Alterations of gut neuropeptides in gastroesophageal reflux disease are resolved after antireflux surgery. 53 62
11182403 2000
31
Parietal cell protrusions and fundic gland cysts during omeprazole maintenance treatment. 53 62
10872661 2000
32
Endogenous cholecystokinin enhances postprandial gastroesophageal reflux in humans through extrasphincteric receptors. 53 62
9721157 1998
33
Effect of long-term gastric acid suppressive therapy on serum vitamin B12 levels in patients with Zollinger-Ellison syndrome. 53 62
9626024 1998
34
Prolongation of the QT interval related to cisapride-diltiazem interaction. 53 62
9545159 1998
35
Effect of gastrin-17 on lower esophageal sphincter characteristics in man. 53 62
9440634 1997
36
Effects of gastroesophageal reflux on the oral cavity. 53 62
9422634 1997
37
The role of motilin and cisapride in the enteric nervous system of the lower esophageal sphincter in humans. 53 62
9413048 1997
38
Duodenal ulcer and gastroesophageal reflux disease today: long-term therapy--a sideways glance. 53 62
9165690 1996
39
Gastroesophageal reflux disease is associated with enteric hormone abnormalities. 53 62
8311131 1994
40
Incidence of gastroesophageal reflux with casein and whey-based formulas. 53 62
8350205 1993
41
Nonulcer dyspepsia: current approaches to diagnosis and management. 53 62
8480563 1993
42
Effect of CCK and its antagonists on gastric emptying. 53 62
8298606 1993
43
Size reduction of gastric fundic gland polyposis by de-escalation of acid-suppressive therapy. 62
35898833 2023
44
Upper Airway Cough Syndrome. 62
36283869 2023
45
Safety and Feasibility of Performing Antireflux Procedures at a Safety Net Hospital. 62
36228341 2023
46
Synergistic enhancement of the phytostabilization of a semiarid mine tailing by a combination of organic amendment and native microorganisms (Funneliformis mosseae and Bacillus cereus). 62
36336022 2023
47
Anti-reflux surgery in children with congenital diaphragmatic hernia: A prospective cohort study on a controversial practice. 62
35618494 2022
48
Incidence of Abnormalities of the Gastric Tube Following Sleeve Gastrectomy and Its Role on Esophagitis Progression. 62
36460942 2022
49
Brachycephalic obstructive airway syndrome: much more than a surgical problem. 62
36342210 2022
50
Artificial intelligence facilitates measuring reflux episodes and postreflux swallow-induced peristaltic wave index from impedance-pH studies in patients with reflux disease. 62
36458529 2022

Variations for Gastroesophageal Reflux

ClinVar genetic disease variations for Gastroesophageal Reflux:

5 (show all 19)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 TAMM41 NM_001284401.2(TAMM41):c.329A>G (p.Tyr110Cys) SNV Pathogenic
1299473 GRCh37: 3:11880778-11880778
GRCh38: 3:11839304-11839304
2 TAMM41 NM_001284401.2(TAMM41):c.806dup (p.Asn269fs) DUP Pathogenic
1299474 GRCh37: 3:11851058-11851059
GRCh38: 3:11809584-11809585
3 CHAT NM_020549.5(CHAT):c.2081C>G (p.Ser694Cys) SNV Pathogenic
523529 rs201439531 GRCh37: 10:50872926-50872926
GRCh38: 10:49664880-49664880
4 CHAT NM_020549.5(CHAT):c.1061C>T (p.Thr354Met) SNV Pathogenic
523528 rs769234940 GRCh37: 10:50835781-50835781
GRCh38: 10:49627735-49627735
5 overlap with 16 genes DEL Pathogenic
1684659 GRCh37:
GRCh38: 16:3619617-4448281
6 ASIC4-AS1, GMPPA NM_013335.4(GMPPA):c.210del (p.Ala71fs) DEL Pathogenic
88694 rs886037654 GRCh37: 2:220366268-220366268
GRCh38: 2:219501546-219501546
7 ABCC8 NM_000352.6(ABCC8):c.1793G>A (p.Arg598Gln) SNV Likely Pathogenic
523361 rs1344172059 GRCh37: 11:17452385-17452385
GRCh38: 11:17430838-17430838
8 ACTL6A NM_004301.5(ACTL6A):c.1129C>T (p.Arg377Trp) SNV Likely Pathogenic
549661 rs868064163 GRCh37: 3:179304340-179304340
GRCh38: 3:179586552-179586552
9 COL5A1 NM_000093.5(COL5A1):c.608G>T (p.Gly203Val) SNV Likely Pathogenic
523328 rs1554781700 GRCh37: 9:137593133-137593133
GRCh38: 9:134701287-134701287
10 ABCC8 NM_000352.6(ABCC8):c.3517G>A (p.Val1173Met) SNV Likely Pathogenic
35609 rs141322087 GRCh37: 11:17426099-17426099
GRCh38: 11:17404552-17404552
11 RPS6KA3 NM_004586.3(RPS6KA3):c.533C>G (p.Ala178Gly) SNV Likely Pathogenic
374121 rs1057518914 GRCh37: X:20211665-20211665
GRCh38: X:20193547-20193547
12 FAM120AOS NM_198841.4(FAM120AOS):c.743C>T (p.Thr248Ile) SNV Likely Pathogenic
183343 rs140119177 GRCh37: 9:96209921-96209921
GRCh38: 9:93447639-93447639
13 ITGA3 NM_002204.4(ITGA3):c.1766G>C (p.Arg589Pro) SNV Uncertain Significance
1339481 GRCh37: 17:48153781-48153781
GRCh38: 17:50076417-50076417
14 SYNE2 NM_182914.3(SYNE2):c.19624G>T (p.Gly6542Trp) SNV Uncertain Significance
598975 rs746433383 GRCh37: 14:64685197-64685197
GRCh38: 14:64218479-64218479
15 CPEB1-AS1, AP3B2 NM_001278512.2(AP3B2):c.881A>C (p.Lys294Thr) SNV Uncertain Significance
807299 rs200983489 GRCh37: 15:83349398-83349398
GRCh38: 15:82680646-82680646
16 RYR1 NM_000540.3(RYR1):c.10097G>T (p.Arg3366Leu) SNV Uncertain Significance
598974 rs137932199 GRCh37: 19:39009932-39009932
GRCh38: 19:38519292-38519292
17 ZNF469 NM_001367624.2(ZNF469):c.2569A>G (p.Asn857Asp) SNV Uncertain Significance
523411 rs1555518955 GRCh37: 16:88496447-88496447
GRCh38: 16:88430039-88430039
18 ZNF469 NM_001367624.2(ZNF469):c.9532G>A (p.Gly3178Ser) SNV Uncertain Significance
523412 rs887755283 GRCh37: 16:88503410-88503410
GRCh38: 16:88437002-88437002
19 ZNF469 NM_001367624.2(ZNF469):c.470G>A (p.Gly157Glu) SNV Uncertain Significance
320853 rs781096189 GRCh37: 16:88494348-88494348
GRCh38: 16:88427940-88427940

Expression for Gastroesophageal Reflux

Search GEO for disease gene expression data for Gastroesophageal Reflux.

Pathways for Gastroesophageal Reflux

Pathways related to Gastroesophageal Reflux according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 13.02 TP53 RPS6KA3 PYY MLN HRH2 GCG
2
Show member pathways
11.38 RPS6KA3 GCG ACTL6A
3 9.4 PYY GCG

GO Terms for Gastroesophageal Reflux

Biological processes related to Gastroesophageal Reflux according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of glial cell proliferation GO:0060253 8.92 ABCC8 TP53

Molecular functions related to Gastroesophageal Reflux according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 9.32 PYY MLN GCG GAST CCK

Sources for Gastroesophageal Reflux

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....